Untitled

[myradella]

Take the First Step - Order (Ruxolitinib) Jakafi Online & Get Started

Embark on a suitable healthcare journey by taking the first step - order your (Ruxolitinib, Phosphate) Jakafi online and kickstart a hassle-free experience. Enjoy the ease of surfing, selecting, and getting your prescribed products at your doorstep. Embrace the future with online ordering—swift, safe, and tailored to your health needs.

[myradella]

FDA Approves Jakafi (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera

The first and only FDA-approved treatment for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea PV is a rare blood cancer associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack1 Jakafi is the only treatment for patients with PV shown to provide consistent hematocrit control, spleen volume reduction and complete hematological remission by targeting the overactive JAK pathway, a critical component of this disease

The approval of Jakafi represents an important advance for patients with uncontrolled PV. For the first time we are able to provide these patients a treatment that has been shown to provide effective and consistent control of their blood counts and reduce spleen volume,” said Srdan Verstovsek, M.D., Ph.D., Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

[myradella]

How should I take Jakafi?

Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider. You can take Jakafi with or without food. Jakafi may also be given through certain nasogastric tubes. o Tell your healthcare provider if you cannot take Jakafi by mouth. Your healthcare provider will decide if you can take Jakafi through a nasogastric tube. o Ask your healthcare provider to give you specific instruction on how to properly take Jakafi through a nasogastric tube.

Do not drink grapefruit juice while taking Jakafi. Grapefruit juice can affect the amount of Jakafi in your blood. If you take too much Jakafi call your healthcare provider or go to the nearest hospital emergency room right away. Take the bottle of Jakafi with you. If you miss a dose of Jakafi, take your next dose at your regular time. Do not take 2 doses at the same time. You will have regular blood tests during your treatment with Jakafi. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests.

[myradella]

Ruxolitinib is used to treat cancer

Possible Side Effects

Bone marrow suppression. This is a decrease in the number of white blood cells, red blood cells, and platelets. This may raise your risk of infection, make you tired and weak (fatigue), and raise your risk of bleeding.

Diarrhea (loose bowel movements)

Headache

Feeling dizzy

Bruising

Infection

Swelling of the hands, feet, or any other part of the body

Risk of severe and life-threatening infections, including tuberculosis, hepatitis B, and shingles, in patients with risk factors for these infections. A rare virus can cause an infection that affects your central nervous system. The central nervous system is made up of your brain and spinal cord. You could feel extreme tiredness, agitation, confusion, have trouble understanding or speaking, trouble thinking and/or memory loss, difficulty walking, eyesight changes, numbness or lack of strength to your arms, legs, face, or body, or seizures. If you start to have any of these symptoms let your doctor know right away. This medicine may raise your risk of getting a second cancer, such as skin cancer. Increase in your cholesterol and triglyceride levels Typical signs and symptoms of your cancer may return when you stop treatment with ruxolitinib. The use of this type of medicine, a JAK inhibitor, for the treatment of rheumatoid arthritis, has been shown to raise the risk of getting a second cancer such as lymphoma and other cancers. This risk is increased in people who currently smoke or have smoked in the past.

[myradella]

Positive Quality Intervention: Ruxolitinib (Jakafi) - Managing Myelofibrosis Patients

Ruxolitinib is a selective JAK2 inhibitor used for the treatment of myelofibrosis (MF). This PQI will review the close monitoring of platelets required to ensure appropriate dose and avoid severe thrombocytopenia due to the therapy.

Ruxolitinib is FDA approved for the treatment of intermediate or high-risk patients with MF. This includes patients with primary MF, post polycythemia vera MF, post-essential thrombocytopenia MF, steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older, and chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. Ruxolitinib is also indicated in polycythemia vera and graft-versus-host disease.

[myradella]

What is ruxolitinib?

Ruxolitinib is a medication used to treat myeloproliferative neoplasms (MPNs). It is licensed for the treatment of patients with myelofibrosis (MF) either primary or occurring after polycythaemia vera (PV) or essential thrombocythaemia (ET). It is under investigation in clinical trials for patients with PV and ET. The drug is known by several names. It goes under the brand name Jakavi® and the molecule is called ruxolitinib. Before this it was known as INC18424 or INC424. If you need more information about JAK2 mutation or the types of MPN or myelofibrosis you can learn more on our website at www.mpnvoice.org.uk Ruxolitinib comes as a capsule and is taken by mouth. Ruxolitnib is currently available in 5mg, 15mg or 20mg white capsules.

How does ruxolitinib work?

Blood cells originate from stem cells. Stem cells are master cells which divide and mature into the different types of blood cells: red blood cells, white blood cells and platelets. The marrow in our bones acts as a factory for the division and maturation of these stem cells into blood cells. Each new blood cell contains DNA which carries all the instructions the cell needs to grow and function. Once the blood cells have matured they leave the bone marrow and enter our blood stream. In MPNs the processes involved in controlling blood cell production are disordered and for most patients this is thought to be due to over activation of JAK2 a protein found in most cells. For about 75% of patients with MPN this over activation is due to a mutation or change in the genetic sequence of JAK known as JAK2V617F.

Ruxolitinib works by interfering with the function of JAK2 and its relation JAK1. This slows down blood cell production and also the production of signalling chemicals known as cytokines.

When you take ruxolitinib the number of blood cells being made decreases so that your bloodstream will be less crowded, your blood will flow more freely, and you will be less likely to suffer a blood clot or thrombosis. Treatment with ruxolitinib also reduces the size of most patients’ spleens towards a more normal size. In addition many of the symptoms, for example sweating, itching, tiredness and pain and fullness after eating which with MF and other MPN patients suffer, improve with ruxolitinib therapy.

You may be asked to sign a consent to treatment form before you start taking ruxolitinib.